Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stake Lifted by Hsbc Holdings PLC

Hsbc Holdings PLC raised its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 6.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 36,631 shares of the company’s stock after buying an additional 2,067 shares during the quarter. Hsbc Holdings PLC’s holdings in Intellia Therapeutics were worth $813,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of NTLA. Blue Trust Inc. boosted its stake in Intellia Therapeutics by 1,664.3% during the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after purchasing an additional 1,398 shares during the period. First Horizon Advisors Inc. boosted its position in shares of Intellia Therapeutics by 22.1% during the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after buying an additional 472 shares during the period. GAMMA Investing LLC grew its holdings in Intellia Therapeutics by 1,322.0% in the 2nd quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock worth $59,000 after buying an additional 2,459 shares in the last quarter. EntryPoint Capital LLC increased its position in Intellia Therapeutics by 61.1% in the 1st quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock valued at $113,000 after acquiring an additional 1,563 shares during the period. Finally, AdvisorNet Financial Inc raised its stake in Intellia Therapeutics by 63.5% during the 2nd quarter. AdvisorNet Financial Inc now owns 5,100 shares of the company’s stock valued at $114,000 after acquiring an additional 1,980 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on NTLA. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 24th. Royal Bank of Canada restated an “outperform” rating and set a $54.00 price target on shares of Intellia Therapeutics in a research report on Thursday, September 19th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a report on Thursday, June 27th. Evercore ISI raised Intellia Therapeutics to a “strong-buy” rating in a report on Friday, August 9th. Finally, Truist Financial reaffirmed a “buy” rating and set a $120.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $61.77.

Intellia Therapeutics Trading Up 2.1 %

NASDAQ NTLA opened at $21.00 on Monday. Intellia Therapeutics, Inc. has a 1 year low of $19.21 and a 1 year high of $34.87. The stock’s 50-day moving average price is $22.73 and its two-hundred day moving average price is $23.83. The company has a market cap of $2.03 billion, a PE ratio of -3.92 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The business had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $19.68 million. The business’s quarterly revenue was down 48.5% on a year-over-year basis. During the same quarter last year, the firm posted ($1.40) EPS. Research analysts forecast that Intellia Therapeutics, Inc. will post -5.22 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.